XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 24, 2020
Jun. 30, 2017
USD ($)
Jun. 30, 2017
EUR (€)
Aug. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jul. 26, 2021
Jul. 08, 2021
shares
Dec. 31, 2020
USD ($)
Dec. 01, 2020
Apr. 26, 2019
Jun. 30, 2017
EUR (€)
Cost of Goods and Services Sold, Total         $ 392,544 $ 266,929 $ 1,612,810 $ 1,169,351            
Collaborative Arrangement, Payment for Research and Development Agreement   $ 1,100,000                        
ID Biologics Inc [Member]                            
Cost of Goods and Services Sold, Total         $ 76,000   $ 132,000              
Novovet [Member]                            
Equity Method Investment, Ownership Percentage                         20.00%  
Alphazyme [Member]                            
Sale of Stock, Percentage of Ownership after Transaction 2.50%                          
Equity Securities without Readily Determinable Fair Value, Amount                     $ 284,709      
BDI Holdings [Member]                            
Proceeds from Sales of Business, Affiliate and Productive Assets       $ 1,600,000                    
Research Services Agreement [Member]                            
Collaborative Arrangement, Payment for Additional Development and Commercialization | €                           € 1,500,000
Service Framework Agreement [Member]                            
Collaborative Arrangement, Minimum Obligation For Research and Development   $ 1,000,000.0                        
Collaborative Arrangement, Duration Of Agreement (Year)   2 years 2 years                      
Collaborative Arrangement, Outstanding Commitment   $ 1,000,000.0                        
BDI Holdings [Member]                            
Ownership Percentage                 16.10%          
VLPBio Member                            
Ownership Percentage                 3.30%          
Alphazyme [Member]                            
Ownership Percentage                       1.99%    
ID Biologics Inc [Member]                            
Investment Owned, Balance, Shares (in shares) | shares                   129,661        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners                   0.37%        
Research Services Agreement [Member]                            
Collaborative Arrangement, Payment for Research and Development Agreement | €     € 1,000,000.0                      
Research Services Agreement [Member] | BDI Holdings [Member]                            
Collaborative Arrangement, Equity Interest Acquired   16.10% 16.10%                      
Collaborative Arrangement, Minimum Obligation For Research and Development | €                           936,000
Collaborative Arrangement, Duration Of Agreement (Year)   2 years 2 years                      
Collaborative Arrangement, Maximum Obligation For Research and Development | €                           8,000,000.0
Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member]                            
Collaborative Arrangement, Minimum Obligation For Research and Development | €                           € 1,000,000
Collaborative Arrangement, Revenue Sharing, Percentage   50.00% 50.00%                      
Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member]                            
Collaborative Arrangement, Revenue Sharing, Percentage   75.00% 75.00%                      
Research Services Agreement [Member] | VLPBio Member                            
Collaborative Arrangement, Equity Interest Acquired   3.30% 3.30%